Even though paroxysmal nocturnal hemoglobinuria (PNH) is rare, there are effective treatments—some of which can potentially cure the condition. However, the treatments have risks that people ...

Regeneron will have a tough job taking on AstraZeneca’s big-selling Ultomiris in the market for paroxysmal nocturnal haemoglobinuria (PNH) therapies – but new biomarker data suggests it could ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended AstraZeneca's oral Factor D inhibitor, Voydeya (danicopan), for marketing authorisation ...

Roche is preparing regulatory filings for its crovalimab antibody for rare disease paroxysmal nocturnal haemoglobinuria (PNH), after a phase 3 trial showed the drug was as effective as AstraZeneca ...

Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH ...

On the instructions of Rameau Normil, Acting Director General of the National Police of Haiti (PNH), Divisional Commissioner ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Haïti National Police in Artibonite arrested nine suspected gang members, including seven tied to the Kokorat San Ras gang ...

On Monday, January 27, 2025, in the early morning, the commune of Kenscoff was attacked by heavily armed individuals who ...

Several sessions focused on paroxysmal nocturnal hemoglobinuria (PNH), highlighting emerging treatment options such as oral monotherapy, and new research on managing the condition. Key sessions ...